The impact of new technologies on vaccines.
Vast changes are taking place in vaccinology consequent to the introduction of new technologies. Amongst the vaccines included in the Expanded Programme of Immunization (EPI), the pertussis vaccine has been replaced by acellular purified fractions devoid of side-effects. Non-pathogenic but immunogenic mutants of tetanus and diptheria toxins are likely to replace the toxoids. An effective vaccine against hepatitis B prepared by recombinant technology is in large-scale use. Conjugated vaccines against Haemophilus influenzae b, S. pneumococcus and meningococcus are now available, as also vaccines against mumps, rubella and measles. Combination vaccines have been devised to limit the number of injections. Vaccine delivery systems have been developed to deliver multiple doses of the vaccine at a single contact point. A genetically-engineered oral vaccine for typhoid imparts better and longer duration of immunity. Oral vaccines for cholera and other enteric infections are under clinical trials. The nose as a route for immunization is showing promise for mucosal immunity and for anti-inflammatory experimental vaccines against multiple sclerosis and insulin-dependent diabetes mellitus. The range of vaccines has expanded to include pathogens resident in the body such as Helicobacter pylori (duodenal ulcer), S. mutans (dental caries), and human papilloma virus (carcinoma of the cervix). An important progress is the recognition that DNA alone can constitute the vaccines, inducing both humoral and cell-mediated immune responses. A large number of DNA vaccines have been made and shown interesting results in experimental animals. Live recombinant vaccines against rabies and rinderpest have proven to be highly effective for controlling these infections in the field, and those for AIDS are under clinical trial. Potent adjuvants have added to the efficacy of the vaccines. New technologies have emerged to 'humanize' mouse monoclonals by genetic engineering and express these efficiently in plants. These recombinant antibodies are opening out an era of highly specific and safe therapeutic interventions. Human recombinant antibodies would be invaluable for treating patients with terminal tetanus and rabies. Antibodies are already in use for treatment of cancer, rheumatoid arthritis and allergies. An advantage of preformed antibodies directed at a defined target and given in adequate amounts is the certainty of efficacy in every recipient, in contrast to vaccines, where the quality and quantum of immune response varies from individual to individual.
Talwar
G P
GP
Talwar Research Foundation, New Delhi, India.
Diwan
M
M
Razvi
F
F
Malhotra
R
R
D000818:Animals; D001709:Biotechnology; D019496:Cancer Vaccines; D022121:Cholera Vaccines; D006801:Humans; D017589:Immunization Programs; D051379:Mice; D014436:Typhoid-Paratyphoid Vaccines; D014612:Vaccines / Q000008:administration & dosage / Q000145:classification; D017778:Vaccines, Combined; D019444:Vaccines, DNA / Q000008:administration & dosage; D014614:Vaccines, Synthetic
D019496:Cancer Vaccines; D022121:Cholera Vaccines; D014436:Typhoid-Paratyphoid Vaccines; D014612:Vaccines; D017778:Vaccines, Combined; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic